Ignite Creation Date:
2024-05-06 @ 1:00 AM
Last Modification Date:
2024-10-26 @ 10:57 AM
Study NCT ID:
NCT01703728
Status:
COMPLETED
Last Update Posted:
2017-05-31
First Post:
2012-10-03
Brief Title:
Controlled Ovarian Stimulation by HP-hMG for IVF ICSI Cycles Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old
Sponsor:
Ferring Pharmaceuticals
Organization:
Ferring Pharmaceuticals
Study Overview
Official Title:
SHOview Observational Study Controlled Ovarian Stimulation by HP-hMG for IVF ICSI Cycles Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SHOview
Brief Summary:
Ovarian hyper stimulation syndrome OHSS is a potentially serious complication of ovarian stimulation in IVF In Vitro Fertilisation The main objective of this study is to describe the incidence of moderate or severe forms of OHSS in women between 18 and 36 years of age treated with HP-hMG
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None